X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2596) 2596
female (1828) 1828
male (1667) 1667
oncology (1633) 1633
adult (1529) 1529
middle aged (1464) 1464
ifosfamide - administration & dosage (1376) 1376
antineoplastic combined chemotherapy protocols - therapeutic use (1367) 1367
ifosfamide (1345) 1345
antineoplastic combined chemotherapy protocols - adverse effects (1181) 1181
ifosfamide - adverse effects (1175) 1175
aged (1109) 1109
chemotherapy (1047) 1047
index medicus (753) 753
adolescent (679) 679
cancer (667) 667
treatment outcome (643) 643
etoposide - administration & dosage (587) 587
cisplatin - administration & dosage (579) 579
cisplatin (498) 498
child (460) 460
ifosfamide - therapeutic use (419) 419
drug administration schedule (394) 394
doxorubicin - administration & dosage (389) 389
lung neoplasms - drug therapy (386) 386
etoposide (374) 374
cisplatin - adverse effects (345) 345
survival rate (342) 342
antineoplastic combined chemotherapy protocols - administration & dosage (329) 329
combined modality therapy (325) 325
child, preschool (318) 318
disease-free survival (316) 316
sarcoma - drug therapy (312) 312
pharmacology & pharmacy (308) 308
etoposide - adverse effects (304) 304
doxorubicin (303) 303
carboplatin - administration & dosage (298) 298
hematology (298) 298
antineoplastic agents, alkylating - adverse effects (289) 289
cyclophosphamide (285) 285
neoplasm staging (282) 282
therapy (279) 279
retrospective studies (264) 264
survival analysis (264) 264
dose-response relationship, drug (259) 259
prognosis (259) 259
sarcoma (255) 255
carboplatin (254) 254
antineoplastic agents - adverse effects (253) 253
children (245) 245
cyclophosphamide - administration & dosage (229) 229
care and treatment (226) 226
young adult (223) 223
mesna - administration & dosage (221) 221
trial (219) 219
vincristine - administration & dosage (216) 216
toxicity (214) 214
remission induction (213) 213
salvage therapy (212) 212
carcinoma, non-small-cell lung - drug therapy (211) 211
pediatrics (210) 210
paclitaxel (207) 207
follow-up studies (205) 205
mesna (203) 203
phase-ii trial (202) 202
neoplasms - drug therapy (199) 199
phase-ii (198) 198
tumors (198) 198
survival (191) 191
risk factors (185) 185
doxorubicin - adverse effects (184) 184
medicine & public health (183) 183
infusions, intravenous (181) 181
prospective studies (181) 181
carboplatin - adverse effects (180) 180
bone neoplasms - drug therapy (179) 179
paclitaxel - administration & dosage (175) 175
antineoplastic agents - therapeutic use (170) 170
antineoplastic agents, alkylating - administration & dosage (168) 168
aged, 80 and over (164) 164
infant (159) 159
methotrexate - administration & dosage (159) 159
neutropenia - chemically induced (158) 158
research (152) 152
cyclophosphamide - adverse effects (151) 151
neoplasm recurrence, local - drug therapy (151) 151
soft tissue neoplasms - drug therapy (151) 151
antineoplastic agents, alkylating - therapeutic use (150) 150
time factors (149) 149
gemcitabine (148) 148
animals (147) 147
carcinoma (147) 147
drug therapy (147) 147
radiotherapy (144) 144
metastasis (141) 141
drug evaluation (139) 139
methotrexate (139) 139
chemotherapy, adjuvant (136) 136
combination chemotherapy (136) 136
combination (133) 133
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2722) 2722
German (51) 51
Japanese (51) 51
French (40) 40
Chinese (25) 25
Polish (10) 10
Spanish (9) 9
Italian (6) 6
Russian (3) 3
Czech (2) 2
Danish (1) 1
Finnish (1) 1
Hungarian (1) 1
Korean (1) 1
Portuguese (1) 1
Serbian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 03/2019, Volume 2019, Issue 3, pp. CD008944 - CD008944
Background Improvements in diagnostics and treatment for paediatric malignancies resulted in a major increase in survival. However, childhood cancer survivors... 
TOTAL-BODY IRRADIATION | Humans | Carboplatin [adverse effects] | GLOMERULAR-FILTRATION-RATE | MEDICINE, GENERAL & INTERNAL | Renal Insufficiency | BILATERAL WILMS-TUMOR | ACUTE LYMPHOBLASTIC-LEUKEMIA | Hypophosphatemia [epidemiology; etiology] | Adult | Antineoplastic Agents [adverse effects] | Radiotherapy [adverse effects] | STEM-CELL TRANSPLANTATION | Ifosfamide [adverse effects] | Child | Hypertension [epidemiology; etiology] | LONG-TERM SURVIVORS | Risk Factors | BONE-MARROW-TRANSPLANTATION | Survivors | Magnesium Deficiency [epidemiology; etiology] | Chronic [epidemiology; etiology] | Nephrectomy [adverse effects] | Cisplatin [adverse effects] | Proteinuria [epidemiology; etiology] | IFOSFAMIDE-INDUCED NEPHROTOXICITY | HIGH-DOSE CHEMOTHERAPY | CHRONIC KIDNEY-DISEASE | Glomerular Filtration Rate [drug effects; physiology; radiation effects] | Magnesium Deficiency - epidemiology | Hypophosphatemia - etiology | Proteinuria - epidemiology | Renal Insufficiency, Chronic - etiology | Magnesium Deficiency - etiology | Ifosfamide - adverse effects | Hypophosphatemia - epidemiology | Radiotherapy - adverse effects | Glomerular Filtration Rate - physiology | Hypertension - etiology | Carboplatin - adverse effects | Renal Insufficiency, Chronic - epidemiology | Glomerular Filtration Rate - drug effects | Glomerular Filtration Rate - radiation effects | Nephrectomy - adverse effects | Antineoplastic Agents - adverse effects | Cisplatin - adverse effects | Hypertension - epidemiology | Proteinuria - etiology | Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2011, Volume 365, Issue 3, pp. 203 - 212
BEACOPP combination chemotherapy was compared with ABVD chemotherapy in advanced Hodgkin's disease. BEACOPP therapy was associated with higher initial rates of... 
CELL TRANSPLANT | MEDICINE, GENERAL & INTERNAL | VINORELBINE | MOPP | DISEASE | REGIMEN | IFOSFAMIDE | CHEMOTHERAPY | STANDARD | HYBRID | FERTILITY | Doxorubicin - therapeutic use | Dacarbazine - adverse effects | Dacarbazine - therapeutic use | Humans | Middle Aged | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Vinblastine - therapeutic use | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Young Adult | Hodgkin Disease - radiotherapy | Bleomycin - therapeutic use | Vinblastine - adverse effects | Hodgkin Disease - drug therapy | Hodgkin Disease - mortality | Adult | Female | Etoposide - adverse effects | Prednisone - adverse effects | Kaplan-Meier Estimate | Proportional Hazards Models | Hematopoietic Stem Cell Transplantation | Etoposide - therapeutic use | Combined Modality Therapy | Bleomycin - adverse effects | Remission Induction | Disease-Free Survival | Procarbazine - adverse effects | Procarbazine - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Hodgkin Disease - therapy | Adolescent | Vincristine - therapeutic use | Vincristine - adverse effects | Neoplasm Staging | Doxorubicin - adverse effects | Prednisone - therapeutic use | Procarbazine | Vinblastine | Disease | Etoposide | Prednisone | Family medical history | Radiation therapy | Patients | Lymphoma | Doxorubicin | Survival | Vincristine | Studies | Hepatitis | Dacarbazine | Cyclophosphamide | Chemotherapy | Bleomycin | Tomography | Lymphomas | Hodgkin's disease
Journal Article
Blood, ISSN 0006-4971, 05/2012, Volume 119, Issue 20, pp. 4619 - 4624
Approximately 5-10% of diffuse large B-cell lymphomas (DLBCL) harbor a 8q24/MYC rearrangement (MYC+). We determined the prognostic significance of MYC... 
REARRANGEMENT | IMPACT | POOR-PROGNOSIS | T(14/18) | IN-SITU HYBRIDIZATION | CLASSIFICATION | HEMATOLOGY | EXPRESSION | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Podophyllotoxin - adverse effects | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Dexamethasone - adverse effects | Male | Transplantation, Autologous | Cytarabine - adverse effects | Cisplatin - administration & dosage | Young Adult | Lymphoma, Large B-Cell, Diffuse - therapy | Melphalan - adverse effects | Immunotherapy | Treatment Failure | Podophyllotoxin - administration & dosage | Adult | Female | Chemotherapy, Adjuvant | Carmustine - adverse effects | Genes, myc - physiology | Dexamethasone - administration & dosage | Etoposide - adverse effects | Lymphoma, Large B-Cell, Diffuse - drug therapy | Ifosfamide - adverse effects | Rituximab | Etoposide - administration & dosage | Combined Modality Therapy | Cytarabine - administration & dosage | Lymphoma, Large B-Cell, Diffuse - mortality | Melphalan - administration & dosage | Ifosfamide - administration & dosage | Cisplatin - adverse effects | Aged | Hematopoietic Stem Cell Transplantation - methods | Antibodies, Monoclonal, Murine-Derived - adverse effects | Lymphoma, Large B-Cell, Diffuse - genetics | Carmustine - administration & dosage | Life Sciences | Biochemistry, Molecular Biology | Lymphoma, Large B-Cell, Diffuse | Podophyllotoxin | methods | Genes, myc | Cytarabine | genetics | administration & dosage | Melphalan | Antibodies, Monoclonal, Murine-Derived | Dexamethasone | drug therapy | Ifosfamide | Carmustine | therapy | Antineoplastic Combined Chemotherapy Protocols | Etoposide | physiology | Hematopoietic Stem Cell Transplantation | Cisplatin | adverse effects | mortality | Medical and Health Sciences | Medicin och hälsovetenskap
Journal Article